DK0506785T3 - Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener - Google Patents

Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener

Info

Publication number
DK0506785T3
DK0506785T3 DK91901622T DK91901622T DK0506785T3 DK 0506785 T3 DK0506785 T3 DK 0506785T3 DK 91901622 T DK91901622 T DK 91901622T DK 91901622 T DK91901622 T DK 91901622T DK 0506785 T3 DK0506785 T3 DK 0506785T3
Authority
DK
Denmark
Prior art keywords
autoantigens
autoimmune diseases
improved treatment
aerosol administration
administration
Prior art date
Application number
DK91901622T
Other languages
Danish (da)
English (en)
Inventor
Howard L Weiner
David A Hafler
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Application granted granted Critical
Publication of DK0506785T3 publication Critical patent/DK0506785T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK91901622T 1989-12-20 1990-12-17 Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener DK0506785T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45480689A 1989-12-20 1989-12-20
PCT/US1990/007455 WO1991008760A1 (en) 1989-12-20 1990-12-17 Improved treatment of autoimmune diseases by aerosol administration of auto antigens

Publications (1)

Publication Number Publication Date
DK0506785T3 true DK0506785T3 (da) 2000-07-24

Family

ID=23806184

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91901622T DK0506785T3 (da) 1989-12-20 1990-12-17 Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener

Country Status (14)

Country Link
EP (1) EP0506785B1 (de)
JP (1) JP2625253B2 (de)
KR (1) KR0185747B1 (de)
AT (1) ATE190496T1 (de)
AU (1) AU642693B2 (de)
BR (1) BR9007950A (de)
CA (1) CA2070281C (de)
DE (1) DE69033487T2 (de)
DK (1) DK0506785T3 (de)
ES (1) ES2144398T3 (de)
GR (1) GR3033634T3 (de)
HU (2) HUT61487A (de)
IL (1) IL96734A (de)
WO (1) WO1991008760A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
BR9007527A (pt) * 1989-07-14 1992-06-23 Autoimmune Inc Metodo para tratar ou prevenir a manifestacao clinica de uma doenca tendo os sintomas de uveoretinite e formulacao farmaceutica para tratar mamiferos sofrendo de uveoretinite
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IL99754A (en) * 1990-10-15 1996-08-04 Autoimmune Inc Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis
JP3712260B2 (ja) * 1992-02-28 2005-11-02 オートイミューン インク 自己免疫疾患のバイスタンダー抑制
JP3845447B2 (ja) * 1992-09-25 2006-11-15 オートイミューン インク タイプ▲ｉｉ▼コラーゲンによるリウマチ性関節炎治療方法
AU674584B2 (en) * 1993-06-02 1997-01-02 Tvw Telethon Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
EP0787147A1 (de) * 1994-10-25 1997-08-06 Immulogic Pharmaceutical Corporation Zhusammensetzung und behandlung von multisklerose
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
BR9706922A (pt) * 1996-01-05 1999-07-20 Autoimmune Inc Método para facilitar a remoção de membrana pericondrial de tecido de cartilagem vertebral não processado para remover proteoglicanos de tecido contendo colágeno tipo ii e para obter um produto contendo colágeno tipo ii
AUPO269996A0 (en) * 1996-10-01 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A method of prophylaxis and treatment
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
SE9902155L (sv) * 1999-06-09 2000-12-10 Bjoern Rydevik Serum antibodies
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
ES2292594T3 (es) 2000-05-24 2008-03-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services E-selectina para tratar o prevenir accidentes cerebrovasculares.
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
WO2004024906A1 (en) 2002-09-13 2004-03-25 UNIVERSITé LAVAL Nucleoside triphosphate diphosphohydrolase (ntpdase 8) and uses thereof
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
EP1910410B1 (de) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Assays zum nachweis von tuberkulose- antigenen, und impfstoffe
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2013134577A2 (en) 2012-03-08 2013-09-12 Detectogen, Inc. Leishmaniasis antigen detection assays and vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US65734A (en) * 1867-06-11 Joseph fantou
US379778A (en) * 1888-03-20 Machine for mitering printers rules
ATE258065T1 (de) * 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
AU645244B2 (en) * 1988-04-08 1994-01-13 Genetics Institute, Llc Bone and cartilage inductive compositions

Also Published As

Publication number Publication date
GR3033634T3 (en) 2000-10-31
KR920703081A (ko) 1992-12-17
JPH05504341A (ja) 1993-07-08
CA2070281A1 (en) 1991-06-21
HU210715A9 (en) 1995-06-28
AU642693B2 (en) 1993-10-28
JP2625253B2 (ja) 1997-07-02
EP0506785A4 (en) 1993-09-08
IL96734A0 (en) 1991-09-16
EP0506785A1 (de) 1992-10-07
HU9202072D0 (en) 1992-09-28
WO1991008760A1 (en) 1991-06-27
DE69033487T2 (de) 2000-06-29
CA2070281C (en) 2005-08-23
HUT61487A (en) 1993-01-28
KR0185747B1 (ko) 1999-05-01
IL96734A (en) 1996-11-14
BR9007950A (pt) 1992-10-27
ATE190496T1 (de) 2000-04-15
DE69033487D1 (de) 2000-04-20
EP0506785B1 (de) 2000-03-15
AU6979191A (en) 1991-07-18
ES2144398T3 (es) 2000-06-16

Similar Documents

Publication Publication Date Title
DK0506785T3 (da) Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener
NO931372L (no) Behandling av autoimmunsykdommer ved oral administrering av autoantigener
EG19304A (en) Method of treating pre-menstrual syndrome
NO923395D0 (no) Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener
ES2190784T3 (es) Supresion de enfermedades autoinmunes por antigenos espectadores.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
DK95091A (da) Anvendelse af acetyl-d-carnitin ved terapeutisk behandling af glaucoma
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
DK221690A (da) Anvendelse af dimethylpolysiloxaner til behandling af sygdomme i det gastrointestinale omraade
NO905414D0 (no) Fremgangsmaate ved sammenfoeying av trematerialer.
NO885287D0 (no) Fremgangsmÿte ved behandling av boreslam.
NO900873L (no) Fremgangsmaate ved fremstilling av sekundaert alkylamin.
NO905050D0 (no) Fremgangsmaate ved behandling av en massestroem.
NO921408L (no) Fremgangsmaate ved behandling av huder
NO885048D0 (no) Fremgangsmÿte ved gassbehandling.
NO910129L (no) Fremgangsmaate for reduksjon av infeksjonsspredning ved hjelp av blodbehandlingsutstyr.
NO895132D0 (no) Anordning ved boelgebrytende molo.